Myeloid Leukemia
Ceflatonin receives U.S. FDA orphan drug designation for treatment of chronic myeloid leukemia
Published in Medical Letter on the CDC and FDA, April 19th, 2006
Ceflatonin is the first of a new class of novel drugs that induces apoptosis (programmed cell death) and inhibits angiogenesis (new blood vessel formation). Ongoing or soon to be initiated clinical trials are and will be evaluating Ceflatonin in a broad range of conditions, including: chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Orphan drug status is granted by the FDA...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Diabetes Diagnostics
Family history of diabetes increased diabetes risk, risk awareness, and risk-reducing behavior - Disease Control
U.S. FDA prohibits use of antiviral drugs in poultry to help keep drugs effective for humans - HIV/AIDS Vaccine Development
HIV serodetection assay differentiates vaccine- from virus-induced antibodies - Obstetrics
Preterm delivery may be affected by gestational weight changes despite prepregnancy weight - Anthrax Pathogenesis
Macrophages play more dominant role than neutrophils in early host defense against anthrax - Avian Influenza
Managed transition would help mitigate risks in pandemic flu outbreak, expert says - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
